Skip to main content
. 2021 Jul 22;12:675322. doi: 10.3389/fphys.2021.675322

FIGURE 4.

FIGURE 4

Decreased atherosclerosis and plasma cholesterol levels in DKO mice treated with the cholesterol absorption blocker ezetimibe for 9 months. (A) Representative images and quantification of plaque accumulation from aortic arch, thoracic and abdominal segments, (B) total plasma cholesterol (CHOL), high density lipoprotein (HDL-C), and triglyceride (TG) levels from HFD-fed DKO mice, and (C) CHOL, HDL-C, and TG levels from HFD-fed Dysf-null mice treated with vehicle or ezetimibe for 9 months. DKO: Vehicle (N = 11), Ezetimibe (N = 7); Dysf: Vehicle (N = 14), Ezetimibe (N = 9); Significance at P < 0.01 (**); P < 0.001 (***); P < 0.0001 (****); Two way ANOVA Sidak’s post hoc tests. Mean + SEM. Scale bar = 0.5 cm.